Ran Zeng Lifeng Luo Xianwen Sun Zhiyao Bao Wei Du Ranran Dai Wei Tang Beili Gao Yi Xiang
10.20517/cdr.2021.98
Cancer Drug Resist
2021 Dec 1;4(4):1019-1027.
brafv600e mutation egfr mutation nsclc case report resistance mechanisms targeted therapy
CC BY
https://pubmed.ncbi.nlm.nih.gov/35582379/
Case Reports
PMC8992450
35582379
EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAFV600E mutation: a case report and review of literature
2021